NPCE

NeuroPace, Inc.

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.

NeuroPace, Inc. (NPCE) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Momentum (C). The rating has held at C+ for 14 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
B-
Factor Score 3.0 / 5.0
Growth
B-
Factor Score 2.9 / 5.0
Profitability
C+
Factor Score 2.7 / 5.0
Momentum
C
Factor Score 2.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -63.4
EV / EBITDA -36.3
Rev Growth YoY 17.1%
Gross Margin 77.4%
Price Return 3M -18.6%
Price Return 12M -10.9%
Catalyst Signal 0.00
Market Cap $412.6M
TTM Revenue $107.0M
Price / Sales 3.9
ROE -103.3%

Historical Factor Score Progression

Held C+ for 14 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B- (3.0) B- (2.9) C+ (2.7) C (2.3) C+ (2.6) C+ (2.7)
2026-11-06 B- (3.0) B- (2.9) C+ (2.8) C (2.3) C+ (2.7) C+ (2.7)
2026-10-30 B- (3.0) B- (2.9) C+ (2.8) C+ (2.7) C+ (2.7) C+ (2.8)
2026-10-23 B- (3.0) B- (2.9) C+ (2.8) C (2.4) C+ (2.6) C+ (2.7)
2026-10-16 B- (3.0) B- (2.9) C+ (2.8) C (2.3) C+ (2.6) C+ (2.7)
Page 1 of 8
…